BioSpace News Archive

Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data supporting the use of its platform to determine HER2 status in patients with metastatic breast cancer will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Quest Diagnostics and Scipher Medicine, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).

Stereotaxis and Baptist Health Lexington announced that physicians have built upon their two-decades of leadership in robotic heart care with the successful treatment of first patients using the newest advancement in the technology, the Genesis Robotic Magnetic Navigation System.

The TIM Company , a leader in commercializing best-in-class proprietary gastrointestinal in vitro technology, is pleased to announce the appointment of Behzad Mahdavi, Ph.D., MBA , as Chief Executive Officer and Board Member.

Anika Therapeutics, Inc. today announced that the first surgeries using the Integrity Implant System were successfully performed by Dr. Christopher Baker at the Florida Orthopaedic Institute in Tampa, FL.

Rhaeos, Inc. proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer.

INVO Bioscience, Inc. today announced the Company received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders’ equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq.

FYR Diagnostics , a pioneering company in the development of liquid biopsy technologies, is thrilled to announce the addition of Dr. Kirk Tanner and Dr. Andy Hill to its Scientific Advisory Board (SAB).

Penumbra, Inc. announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).

Stealth BioTherapeutics Inc. today announced that Reenie McCarthy , Chief Executive Officer, will participate at OIS XIII: Ophthalmology Innovation Summit (OIS) taking place in San Diego, California on Saturday, December 2, at 11:05 AM PT.